Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
Status:
Not yet recruiting
Trial end date:
2024-09-20
Target enrollment:
Participant gender:
Summary
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral
immune response against the aquaporin-4(AQP-4) water channel. Baricitinib is an oral Janus
kinase (JAK)1/JAK2 inhibitor that blocks the upregulated JAK-STAT pathway in patients with
neuroimmune disorders, which is important in bone marrow regulation of B cell proliferation
and differentiation. Baricitinib may benefit some patients with NMOSD due to the important
role of B cells in the pathogenesis of NMOSD. Clincial trials may be needed to observe its
efficacy and safety.